These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1139 related articles for article (PubMed ID: 21960707)

  • 21. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
    Nielsen TO; Leung SCY; Rimm DL; Dodson A; Acs B; Badve S; Denkert C; Ellis MJ; Fineberg S; Flowers M; Kreipe HH; Laenkholm AV; Pan H; Penault-Llorca FM; Polley MY; Salgado R; Smith IE; Sugie T; Bartlett JMS; McShane LM; Dowsett M; Hayes DF
    J Natl Cancer Inst; 2021 Jul; 113(7):808-819. PubMed ID: 33369635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
    J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for developing Ki67 as a useful biomarker in breast cancer.
    Denkert C; Budczies J; von Minckwitz G; Wienert S; Loibl S; Klauschen F
    Breast; 2015 Nov; 24 Suppl 2():S67-72. PubMed ID: 26283598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.
    Goncalves R; DeSchryver K; Ma C; Tao Y; Hoog J; Cheang M; Crouch E; Dahiya N; Sanati S; Barnes M; Sarian LOZ; Olson J; Allred DC; Ellis MJ
    Breast Cancer Res Treat; 2017 Sep; 165(2):355-364. PubMed ID: 28612227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
    Leung SCY; Nielsen TO; Zabaglo LA; Arun I; Badve SS; Bane AL; Bartlett JMS; Borgquist S; Chang MC; Dodson A; Ehinger A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hugh JC; Kos Z; Laenkholm AV; Mastropasqua MG; Moriya T; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Sakatani T; Salgado R; Starczynski J; Sugie T; van der Vegt B; Viale G; Hayes DF; McShane LM; Dowsett M;
    Histopathology; 2019 Aug; 75(2):225-235. PubMed ID: 31017314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; A'Hern R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1024s-1030s. PubMed ID: 16467120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.
    Arens N; Bleyl U; Hildenbrand R
    Virchows Arch; 2005 May; 446(5):489-96. PubMed ID: 15838646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer.
    Rimm DL; Leung SCY; McShane LM; Bai Y; Bane AL; Bartlett JMS; Bayani J; Chang MC; Dean M; Denkert C; Enwere EK; Galderisi C; Gholap A; Hugh JC; Jadhav A; Kornaga EN; Laurinavicius A; Levenson R; Lima J; Miller K; Pantanowitz L; Piper T; Ruan J; Srinivasan M; Virk S; Wu Y; Yang H; Hayes DF; Nielsen TO; Dowsett M
    Mod Pathol; 2019 Jan; 32(1):59-69. PubMed ID: 30143750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
    Ellis MJ; Lin L; Crowder R; Tao Y; Hoog J; Snider J; Davies S; DeSchryver K; Evans DB; Steinseifer J; Bandaru R; Liu W; Gardner H; Semiglazov V; Watson M; Hunt K; Olson J; Baselga J
    Breast Cancer Res Treat; 2010 Jan; 119(2):379-90. PubMed ID: 19844788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial.
    Newell M; Mackey JR; Bigras G; Alvarez-Camacho M; Goruk S; Ghosh S; Schmidt A; Miede D; Chisotti A; Postovit L; Baker K; Mazurak V; Courneya K; Berendt R; Dong WF; Wood G; Basi SK; Joy AA; King K; Meza-Junco J; Zhu X; Field C
    BMJ Open; 2019 Sep; 9(9):e030502. PubMed ID: 31530611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.
    Faragalla H; Plotkin A; Barnes P; Lu FI; Kos Z; Mulligan AM; Bane A; Nofech Mozes S
    Curr Oncol; 2023 Mar; 30(3):3079-3090. PubMed ID: 36975446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
    Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
    BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
    Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
    J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the Ki67 labeling index: a Japanese validation ring study.
    Niikura N; Sakatani T; Arima N; Ohi Y; Honma N; Kanomata N; Yoshida K; Kadoya T; Tamaki K; Kumaki N; Iwamoto T; Sugie T; Moriya T
    Breast Cancer; 2016 Jan; 23(1):92-100. PubMed ID: 24794952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.